Novel ALL treatment strategies: CAR T-cells

Novel ALL treatment strategies: CAR T-cells

VJHemOnc

1 year
147 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
CAR T-cells are a universally exciting area in hematological oncology. Speaking from the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA, Elias Jabbour, MD, of the University of Texas MD Anderson Cancer Center, Houston, TX, discusses the landscape of CAR T-cell therapy for acute lymphoblastic leukemia (ALL). He covers the approval of the CAR T-cell product tisagenlecleucel for pediatric and adolescent ALL based on data from the Phase II ELIANA trial (NCT02435849). Dr Jabbour also discusses the landscape of this field moving forwards, including the potentially game-changing use of off-the-shelf allogeneic CAR T-cell therapy.
Up Next Autoplay
IASLC on Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection
IASLC on Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection
Category: Non-Small Cell Lung Cancer
9 Views
University of Torino 1 day
Oncopeptides to Highlight Data from Melflufen Clinical Program in Multiple Myeloma and AL Amyloidosis in Six Presentations at ASH Annual Meeting 2019
Oncopeptides to Highlight Data from Melflufen Clinical Program in Multiple Myeloma and AL Amyloidosis in Six Presentations at ASH Annual Meeting 2019
Category: News
19 Views
Cancer-News 1 day
Phase I/II Study of Ruxolitinib @SeattleCCA @heidigraydrezn5 @UWashOBGYN
Phase I/II Study of Ruxolitinib @SeattleCCA @heidigraydrezn5 @UWashOBGYN
Category: Ovarian Cancer
22 Views
SeattleCCA 6 days
CDX-1140 Shows Clinical and Biological Efficacy in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Studies
CDX-1140 Shows Clinical and Biological Efficacy in Patients with Advanced Solid Tumors in Phase 1 Dose Escalation Studies
Category: Immunotherapy
12 Views
Cancer-News 6 days
Immune and Circulating Tumor DNA Profiling #NSCLC @MDAndersonNews
Immune and Circulating Tumor DNA Profiling #NSCLC @MDAndersonNews
Category: Non-Small Cell Lung Cancer
9 Views
MD Anderson 6 days
KY1044 Targets ICOS @kymabltd @rcasainson
KY1044 Targets ICOS @kymabltd @rcasainson
Category: Other
3 Views
Cancer-News 6 days
What Mechanism of Action is the Most Relevant for Targeting ICOS? @rcasainson @KymabLtd
What Mechanism of Action is the Most Relevant for Targeting ICOS? @rcasainson @KymabLtd
Category: Other
7 Views
Cancer-News 6 days
DNA Profiling Following Radiation Treatment in #NSCLC @MDAndersonNews
DNA Profiling Following Radiation Treatment in #NSCLC @MDAndersonNews
Category: Non-Small Cell Lung Cancer
26 Views
MD Anderson 6 days
New Findings for KY1044 Anti-ICOS Program at the #CICON2019 Annual Meeting @kymabltd @rcasainson
New Findings for KY1044 Anti-ICOS Program at the #CICON2019 Annual Meeting @kymabltd @rcasainson
Category: Other
12 Views
Cancer-News 6 days
Ideal Management of Steroid Refractory in GVHD @OSUCCC_James
Ideal Management of Steroid Refractory in GVHD @OSUCCC_James
Category: News
10 Views
OSUCCC 1 week